Clinical Trials

Esophageal Neoplasms

NCT06610734 2026-02-09

SKY

202 enrolled

Phase EARLY_PHASE1 Active not recruiting

Small Cell Lung Cancer Extensive Stage

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT07385989 2026-02-04

Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma

Phase 2 Active not recruiting

40 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05621707 2026-02-02

RICE

50 enrolled

Phase 1/2 Active not recruiting

Esophageal Neoplasms

NCT06710847 2026-02-02

SYLVER

14 enrolled

GastrointestinalGynecologic

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06627712 2026-01-30

SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC

Phase 3 Recruiting

318 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05166239 2026-01-23

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Phase 2 Completed

66 enrolled

Phase 1 Not yet recruiting

Carcinoma, Hepatocellular

NCT07363369 2026-01-23

Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

10 enrolled

Advanced Malignant Solid Tumors

NCT07364305 2026-01-23

Lalo

50 enrolled

ICC

NCT04995003 2026-01-22

HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma

Phase 1 Recruiting

25 enrolled

Sarcoma

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial

NCT06190275 2026-01-21

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

Phase NA Recruiting

12 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Phase EARLY_PHASE1 Not yet recruiting

30 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07349836 2026-01-20

Application of mRNA Immunotherapy Technology in EB Virus Related Diseases

40 enrolled

EBV-associated Tumors

NCT07339488 2026-01-14

ILDR-03

Phase 2 Active not recruiting

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

40 enrolled

Advanced Refractory Solid Tumors

NCT05348668 2026-01-07

Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

78 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07277777 2026-01-06

125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors

90 enrolled

Neoplasms, Recurrence

NCT07317778 2026-01-05

Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

249 enrolled

Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT07230639 2025-12-26

MODIFI-CC

52 enrolled

Neoadjuvant Therapies

NCT07279077 2025-12-26

MODIFI-L

38 enrolled

Colonic Neoplasms

NCT07171606 2025-12-18

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

240 enrolled

First-line Advanced NSCLC Patients

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Phase 1/2 Recruiting

144 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT05013450 2025-12-17

Dupilumab_Metastatic NSCLC

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06349837 2025-12-17

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

Phase 1 Recruiting

24 enrolled

Solid Tumor

NCT07285395 2025-12-16

AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study

Phase 1 Recruiting

12 enrolled

Advanced Solid Tumors

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled